G. Mcclorey and M. Wood, An overview of the clinical application of antisense oligonucleotides for RNA-targeting therapies, Current Opinion in Pharmacology, vol.24, pp.52-58, 2015.
DOI : 10.1016/j.coph.2015.07.005

K. Lim, R. Maruyama, and T. Yokota, Eteplirsen in the treatment of Duchenne muscular dystrophy, Drug Design, Development and Therapy, vol.11, pp.533-545, 2017.
DOI : 10.2147/DDDT.S97635

D. Corey and . Nusinersen, Nusinersen, an antisense oligonucleotide drug for spinal muscular atrophy, Nature Neuroscience, vol.20, pp.497-499, 2017.
DOI : 10.1212/WNL.0000000000002445

E. Hoffman, R. Brown, and L. Kunkel, Dystrophin: The protein product of the Duchenne muscular dystrophy locus PMID: 3319190 arthritis mouse models, Cell. Mol Ther, vol.51, issue.16, pp.919-928, 1987.

D. Ittig, S. Liu, D. Renneberg, D. Schümperli, and C. Leumann, Nuclear antisense effects in cyclophilin A pre-mRNA splicing by oligonucleotides: a comparison of tricyclo-DNA with LNA, Nucleic Acids Research, vol.32, issue.1, pp.346-53, 2004.
DOI : 10.1093/nar/gkh187

J. Roberts, E. Palma, P. Sazani, H. Ørum, M. Cho et al., Efficient and Persistent Splice Switching by Systemically Delivered LNA Oligonucleotides in Mice, Molecular Therapy, vol.14, issue.4, pp.471-475, 2006.
DOI : 10.1016/j.ymthe.2006.05.017

A. Yates, W. Akanni, M. Amode, D. Barrell, K. Billis et al., Ensembl 2016, Nucleic Acids Research, vol.44, issue.D1, pp.710-716, 2016.
DOI : 10.1093/nar/gkv1157

URL : http://doi.org/10.1093/nar/gkv1157

W. Kent, C. Sugnet, T. Furey, and K. Roskin, The Human Genome Browser at UCSC, Genome Research, vol.12, issue.6, pp.996-1006, 2002.
DOI : 10.1101/gr.229102

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC186604

K. Mamchaoui, C. Trollet, A. Bigot, E. Negroni, S. Chaouch et al., Immortalized pathological human myoblasts: towards a universal tool for the study of neuromuscular disorders, Skeletal Muscle, vol.1, issue.1, pp.34-22040608, 2011.
DOI : 10.1089/hum.2008.163

URL : https://hal.archives-ouvertes.fr/inserm-00651121

T. Winter, C. Heemskerk, H. Karnaoukh, T. Van-putten, M. De-kimpe et al., Long-term Exon Skipping Studies With 2'-O-Methyl Phosphorothioate Antisense Oligonucleotides in Dystrophic Mouse Models, Mol Ther Nucleic Acids Nucleic Acids, vol.1, pp.43-23344236, 2012.

L. V. Anderson and K. Davison, Multiplex Western Blotting System for the Analysis of Muscular Dystrophy Proteins, The American Journal of Pathology, vol.154, issue.4, pp.1017-1022, 1999.
DOI : 10.1016/S0002-9440(10)65354-0

A. Aartsma-rus, L. Van-vliet, M. Hirschi, A. Janson, H. Heemskerk et al., Guidelines for Antisense Oligonucleotide Design and Insight Into Splice-modulating Mechanisms, Molecular Therapy, vol.17, issue.3, pp.548-553, 2009.
DOI : 10.1038/mt.2008.205

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2835096

L. Popplewell, C. Trollet, G. Dickson, and I. Graham, Design of Phosphorodiamidate Morpholino Oligomers (PMOs) for the Induction of Exon Skipping of the Human DMD Gene, Molecular Therapy, vol.17, issue.3, pp.554-561, 2009.
DOI : 10.1038/mt.2008.287

Z. Pramono, K. Wee, J. Wang, Y. Chen, Q. Xiong et al., Gene, Human Gene Therapy, vol.23, issue.7, pp.781-790, 2012.
DOI : 10.1089/hum.2011.205

A. Aartsma-rus, H. Houlleberghs, J. Van-deutekom, G. Van-ommen, and P. Hoen, Exonic Sequences Provide Better Targets for Antisense Oligonucleotides Than Splice Site Sequences in the Modulation of Duchenne Muscular Dystrophy Splicing, Oligonucleotides, vol.20, issue.2, pp.69-77, 2010.
DOI : 10.1089/oli.2009.0215

E. Zubrzycka-gaarn, D. Bulman, G. Karpati, A. Burghes, B. Belfall et al., The Duchenne muscular dystrophy gene product is localized in sarcolemma of human skeletal muscle, Nature, vol.333, issue.6172, pp.466-469, 1988.
DOI : 10.1038/333466a0

A. Aartsma-rus, M. Bremmer-bout, A. Janson, J. Den-dunnen, G. Van-ommen et al., Targeted exon skipping as a potential gene correction therapy for Duchenne muscular dystrophy, Neuromuscular Disorders, vol.12, issue.1, pp.71-77, 2002.
DOI : 10.1016/S0960-8966(02)00086-X

J. Van-deutekom, A. Janson, I. Ginjaar, W. Frankhuizen, A. Aartsma-rus et al., Local Dystrophin Restoration with Antisense Oligonucleotide PRO051, New England Journal of Medicine, vol.357, issue.26, pp.2677-86, 2007.
DOI : 10.1056/NEJMoa073108

A. Aartsma-rus, A. Janson, W. Kaman, M. Bremmer-bout, J. Den-dunnen et al., Therapeutic antisense-induced exon skipping in cultured muscle cells from six different DMD patients, Human Molecular Genetics, vol.12, issue.8, pp.907-921, 2003.
DOI : 10.1093/hmg/ddg100

N. Goemans, M. Tulinius, J. Van-den-akker, B. Burm, P. Ekhart et al., Systemic Administration of PRO051 in Duchenne's Muscular Dystrophy, New England Journal of Medicine, vol.364, issue.16, pp.1513-1522, 2011.
DOI : 10.1056/NEJMoa1011367

Y. Echigoya, V. Mouly, L. Garcia, T. Yokota, and W. Duddy, In Silico Screening Based on Predictive Algorithms as a Design Tool for Exon Skipping Oligonucleotides in Duchenne Muscular Dystrophy, PLOS ONE, vol.34, issue.3, pp.1-24, 2015.
DOI : 10.1371/journal.pone.0120058.s015

URL : https://hal.archives-ouvertes.fr/hal-01233078

S. Wilton, A. Fall, P. Harding, G. Mcclorey, C. Coleman et al., Antisense Oligonucleotide-induced Exon Skipping Across the Human Dystrophin Gene Transcript, Molecular Therapy, vol.15, issue.7, pp.1288-96, 2007.
DOI : 10.1038/sj.mt.6300095

A. Aartsma-rus, D. Winter, C. Janson, A. Kaman, W. Van-ommen et al., Functional Analysis of 114 Exon-Internal AONs for Targeted DMD Exon Skipping: Indication for Steric Hindrance of SR Protein Binding Sites, Oligonucleotides, vol.15, issue.4, pp.284-297, 2005.
DOI : 10.1089/oli.2005.15.284

E. Caceres, L. Hurst, E. Cáceres, and L. Hurst, The evolution, impact and properties of exonic splice enhancers, Genome Biology, vol.14, issue.12, pp.143-24359918, 2013.
DOI : 10.1093/molbev/msp219

A. Schüler, A. Ghanbarian, and L. Hurst, Purifying Selection on Splice-Related Motifs, Not Expression Level nor RNA Folding, Explains Nearly All Constraint on Human lincRNAs, Molecular Biology and Evolution, vol.31, issue.12, pp.3164-3183, 2014.
DOI : 10.1093/molbev/msu249

K. Lennox and M. Behlke, Chemical modification and design of anti-miRNA oligonucleotides, Gene Therapy, vol.1, issue.12, pp.1111-1120, 2011.
DOI : 10.1261/rna.2533811

T. Yamamoto, H. Yasuhara, F. Wada, M. Harada-shiba, T. Imanishi et al., Superior silencing by 2',4'- BNA(NC)-based short antisense oligonucleotides compared to 2',4'-BNA/LNA-based apolipoprotein B antisense inhibitors, J Nucleic Acids, vol.2012, p.23056920, 2012.
DOI : 10.1155/2012/707323

URL : http://doi.org/10.1155/2012/707323

E. Kandimalla, A. Manning, C. Lathan, R. Byrn, and S. Agrawal, Design, biochemical, biophysical and biological properties of cooperative antisense oligonucleotides, Nucleic Acids Research, vol.23, issue.17, pp.3578-3584, 1995.
DOI : 10.1093/nar/23.17.3578

URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC307240/pdf

S. Obad, C. Santos, A. Petri, M. Heidenblad, O. Broom et al., Silencing of microRNA families by seed-targeting tiny LNAs, Nature Genetics, vol.442, issue.4, pp.371-378, 2011.
DOI : 10.1074/mcp.M800029-MCP200